<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656782</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC imaging survey</org_study_id>
    <nct_id>NCT04656782</nct_id>
  </id_info>
  <brief_title>EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol</brief_title>
  <official_title>Towards Standardization of mCRC Imaging - an EORTC-endorsed, Prospective European Multicenter Imaging Survey and Imaging Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EORTC Imaging Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EORTC Gastrointestinal Tract Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Oncologic Imaging (ESOI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Gastrointestinal and Abdominal Radiology (ESGAR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter imaging Delphi survey among European radiological societies for&#xD;
      mCRC imaging standardization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Computed Tomography (CT) is the imaging reference standard for initial staging&#xD;
      and response assessment in randomized, controlled clinical trials (RCT) dealing with&#xD;
      metastatic colorectal cancer (mCRC). However, comparability of imaging data among recruiting&#xD;
      centers in RCTs is highly hampered by diverging imaging protocols and different technical&#xD;
      specifications. Over the last years, analysis of radiomic features in mCRC patients has&#xD;
      gained increasing interest for image evaluation beyond the mere assessment of extent. Also,&#xD;
      these radiomic features are highly susceptible to technical parameters such as slice&#xD;
      thickness. Hence, comparability of radiomic features among recruiting centers are also highly&#xD;
      limited due to diverging imaging protocols.&#xD;
&#xD;
      AIMS: This prospective, multicenter imaging survey aims at assessing current differences&#xD;
      regarding mCRC CT imaging protocols and technical specifications among large academic sites&#xD;
      in Europe and at drafting a consensus imaging protocol endorsed by the European Organisation&#xD;
      for Research and Treatment of Cancer (EORTC).&#xD;
&#xD;
      METHODS: This survey will be in close cooperation of the EORTC Imaging Group, EORTC&#xD;
      Gastro-intestinal Tract Group, European Society of Oncologic Imaging (ESOI) and European&#xD;
      Society of Gastrointestinal and Abdominal Radiology (ESGAR). Among the EORTC Imaging Group,&#xD;
      EORTC Gastro-intestinal Tract Group, ESOI and ESGAR, imaging experts will be prospectively&#xD;
      recruited and will serve as expert panelists in this prospective survey. Following the Delphi&#xD;
      approach for survey conduction, several survey rounds will be performed. The answers of each&#xD;
      survey round will be analyzed by the survey facilitators, blinded results will then be&#xD;
      forwarded to the expert panelists prior to every following survey round. Statements / answers&#xD;
      can then be modified by the expert panelists in the following survey round.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized imaging protocol consensus among panelists</measure>
    <time_frame>6 months after finalization of the last survey round</time_frame>
    <description>Standardized imaging protocol among panelists after multiple rounds of Delphi consensus survey (technical parameters, e. g. contrast phases, oral contrast etc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of technical comparability of datasets for radiomic and AI analyses</measure>
    <time_frame>6 months after finalization of the last survey round</time_frame>
    <description>During the Delphi-survey, local information regarding technical specifications in their departments (e. g. vendor, scanner type, contrast phases, slice thickness, oral contrast, kV, etc.) will be enquired. The results will be reported as descriptive statistics, e. g. on percentage distribution of a particular technical feature. This analyses will be performed with special regards to technical parameters that knowingly have a major impact on reproducibility of Radiomics features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of heterogeneity of mCRC imaging protocols</measure>
    <time_frame>6 months after finalization of the last survey round</time_frame>
    <description>During the Delphi-survey, local information regarding technical specifications in their departments (e. g. vendor, scanner type, contrast phases, slice thickness, oral contrast, kV, etc.) will be enquired. The results will be reported as descriptive statistics, e. g. on percentage distribution of a particular technical feature.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Expert panelists</arm_group_label>
    <description>Expert panelists will be recruited from EORTC Imaging Group, EORTC GI Group, ESOI and ESGAR and will actively participate in the imaging survey rounds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facilitators</arm_group_label>
    <description>The two central facilitators will moderate and guide the survey rounds. Blinded results will be forwarded to the expert panelists by the facilitators. Further Survey rounds will be adapted by the facilitators according to the previous answers given by the panelists.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging survey</intervention_name>
    <description>Participation as expert panelist in the imaging survey.</description>
    <arm_group_label>Expert panelists</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Facilitation</intervention_name>
    <description>Moderation and evaluation of the expert panel's answers. Adoption and moderation of further survey rounds.</description>
    <arm_group_label>Facilitators</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Imaging experts will serve as expert panelists in the Delphi Survey and will undergo&#xD;
        several rounds of blinded questionnaires.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Researchers / academics with expertise in gastro-intestinal / oncologic imaging&#xD;
&#xD;
          -  Association with EORTC Imaging Group, EORTC GI Group, ESGAR or ESOI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants not meeting the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Unterrainer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Radiology, University Hospital, LMU Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang G Kunz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Radiology, University Hospital, LMU Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Radiology, University Hospital, LMU Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.eortc.org/blog/category/imaging-group/</url>
    <description>EORTC Imaging Group</description>
  </link>
  <link>
    <url>https://www.eortc.org/blog/category/gastrointestinal-tract-cancer-group/</url>
    <description>EORTC Gastrointestinal Tract Cancer Group</description>
  </link>
  <link>
    <url>http://www.esoi-society.org/</url>
    <description>European Society of Oncologic Imaging</description>
  </link>
  <link>
    <url>https://www.esgar.org/</url>
    <description>European Society of Gastrointestinal and Abdominal Radiology</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Marcus Unterrainer</investigator_full_name>
    <investigator_title>Resident, Department of Radiology, University Hospital, LMU Munich</investigator_title>
  </responsible_party>
  <keyword>Computed Tomography (CT)</keyword>
  <keyword>Radiomics</keyword>
  <keyword>Delphi Survey</keyword>
  <keyword>PET/CT</keyword>
  <keyword>Expert Panelists</keyword>
  <keyword>Standardization</keyword>
  <keyword>Imaging protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

